In this article, Samantha Lane of the UK’s Drug Safety Research Unit discusses the development of an evidence-based medicine (EBM) methodology to assess the positive impact of withdrawing or revoking licences for medicines on public health. The approach leverages electronic health records to model the estimated number of adverse reactions prevented by withdrawing drugs from the market and aims to aid regulators in making these decisions in future.
Withdrawing drugs over safety concerns requires careful analysis of the health benefits and risks by regulators.1 But while data on adverse reactions is rightly used to help with these decisions, there is currently no additional modelling on the positive impact regulatory action could have on public health.
Our research paper, which is being submitted for publication this summer, aims to create an evidence-based medicine (EBM) methodology that can assess this positive impact, to further help regulators determine appropriate risk minimisation measures.
Supporting regulators
Monitoring and studying the side effects of licensed medicines is an essential part of drug development to ensure public safety. Known as pharmacovigilance, our epidemiological research records and investigates adverse drug reactions when medicines are used by the general public. This is usually on a much larger scale than is possible in clinical trials and can uncover less common side effects.2
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
National regulators use pharmacovigilance research when deciding whether risk minimisation measures should be imposed. The most severe measures are temporary or permanent product withdrawals.3
To aid decisions about potential product withdrawals, we set out to develop a new EBM methodology to show the positive impact this could have; with quantifiable modelling of the estimated number of adverse reactions that would be prevented if a specific drug was withdrawn from use.
Study focus
Our research looked at products that were voluntarily withdrawn, or had their licence revoked or suspended within the EU for a safety reason between 2012 and 2016. It focused on data from France, Germany and the UK.
Six products were withdrawn or revoked for safety reasons during the study period.
The withdrawn drugs were:
meprobamate – a sedative used to treat anxiety
nicotinic acid/laropiprant – used to lower cholesterol
almitrine – a respiratory stimulant
calcitonin – able to controls calcium levels, it was used for conditions such as osteoporosis.
The revoked drugs were:
some formulations of metoclopramide – an anti-sickness medication
some formulations of domperidone – used to prevent sickness and nausea.
Three products were suspended:
cyproterone acetate/ethinylestradiol (Diane-35 and generics) – birth control
tetrazepam – a muscle relaxant
ketoconazole – an antifungal medicine.
Real-world data and results
Real-world data was gathered from IQVIA Medical Research Data (IMRD) electronic health records (eHR) databases for France, Germany and the UK to find out how many patients were using each drug during the 12 months before and after regulatory action. An estimate of how many people were exposed to the drug each year prior to withdrawal or suspension was calculated.
Then European Medicines Agency (EMA) records were used to identify adverse drug reactions, and a systematic review was carried out to quantify the risk of adverse drug reactions in patients exposed to each withdrawn drug.
The types of adverse drug reactions examined included low blood pressure, diabetes, cancer, bleeding, involuntary movements and weight loss.
An absolute risk for each withdrawn drug was calculated using published literature. This risk, expressed as a percentage of people using the drug, was based on the estimated annual number of people exposed and the number of adverse reactions.
An estimate of the number of adverse reactions prevented as a result of each product withdrawal, revocation or suspension was also calculated based on the exposure and absolute risk figures. The total was an estimated 3,020 per year.
Limitations
There were, of course, limitations to the study. Most notably, we found that usage of the withdrawn drugs did not always drop to zero within 12 months of regulatory action. This could have been because other strengths and formulations that remained on the market were misclassified. In the case of the anxiety medicine meprobamate, we know this was gradually withdrawn over the duration of our study period. Meanwhile, some suspended drugs were returned to the market.
The dataset for Germany included medicine exposures in secondary care (hospital patients), but this was not available for the databases of France and the UK. Therefore, it is possible that exposure estimates in France and the UK are less accurate, and the public health impact of medicine withdrawals and suspensions in these populations may have been underestimated.
Similarly, the data we used does not record over-the-counter medicines used by patients, which could impact outcomes. While pooling data from different sources, as per our methodology for calculating absolute risk of each event, may not always be appropriate.
Wider benefits and future research
Pharmacovigilance measures are never imposed lightly. But quantifiable evidence of the predicted positive impact of regulatory actions on public health will help regulators make these decisions”
One of the key benefits of our research is that the new EBM methodology can be applied to any other drug where usage can be measured. It can be employed with any database where exposure can be estimated and the results can be stratified by demographics and patient subgroups, such as older people, if data allows.
Pharmacovigilance measures are never imposed lightly. But quantifiable evidence of the predicted positive impact of regulatory actions on public health will help regulators make these decisions in future.
This is one of several studies underway at the UK’s independent Drug Safety Research Unit (DSRU) looking at new methodologies to quantify the impact of pharmacovigilance measures. We plan to broaden our research to look at the impact of other marketing authorisation restrictions, such as limiting use to specific age groups, and the public health impact of people switching to alternative drugs when their current treatment is withdrawn.
Our research was carried out under the auspices of the DSRU’s Institute of Pharmacovigilance Sciences and the European Network of Centres of Pharmacoepidemiology and Pharmacovigilance (ENCePP).
DSRU’s Institute focuses on EBM methodology research, including expanding existing benefit-risk evaluation methods, as well as developing new methods, such as the application of artificial intelligence in pharmacovigilance. Researchers also study the long-term effects of medicines and vaccines, as well as the safety of new and advanced products.
About the author
Samantha Lane is a Senior Research Fellow and pharmacoepidemiologist at the Drug Safety Research Unit (DSRU), where she is mainly involved in methodological research under the Institute of Pharmacovigilance Sciences. Samantha often assists with study design and statistical analysis, and has experience with the CPRD electronic health records database. She has a background in Biomedical Science and has trained in Epidemiology, gaining an MSc from The London School of Hygiene & Tropical Medicine (LSHTM), and holds a PgD in Pharmacovigilance.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.